Shares of pharma major Lupin were trading in the green and 1% above on 1 November after the company announced that it had received the EIR (establishment inspection report) from USFDA (the US Food and Drug Administration) for its Mandideep Unit-2 manufacturing facility.

The regulator had conducted an inspection of the facility between 7 – 11 August and closed with an NAI (No Action Indicated) classification.

Nilesh Gupta, managing director of Lupin, said, “We are pleased to receive the EIR with a satisfactory inspection status from the USFDA for the recent inspection of our Mandideep Unit-2 facility. This accomplishment is in line with our continued focus and commitment to becoming best-in-class in quality and compliance, and enables us to continue delivering quality affordable healthcare solutions globally.”

The company also announced that the Board of Directors of the company are set to meet on 8 November to consider and take on record the unaudited financial results for the July-September quarter.

In October, the company received approval from the USFDA for its ANAD (abbreviated new drug application) for Fluconazole tablets. The drug is an equivalent of Diflucan tablets by Pfizer; this modification prevents and treats yeast of fungal infections.

At 11:08 am, the shares of Lupin were trading 0.97% above at Rs 1,139.05 on NSE.